Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Penn-Trafford sophomore Abby Rayman is on a mission to raise $10,000 to support children diagnosed with leukemia and lymphoma ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

Stifel analysts increased the price target on Nurix Therapeutics Inc . (NASDAQ:NRIX) shares to $36.00, up from the previous target of $34.00, while reaffirming their Buy rating on the stock. The ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s ...

In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Verastem (VSTM – Research Report), with a price ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.